BELL Stock Overview
Develops and commercialize oxygen related medical device products in the United States. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Belluscura plc Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | UK£0.095 |
| 52 Week High | UK£0.27 |
| 52 Week Low | UK£0.07 |
| Beta | 1.14 |
| 11 Month Change | -9.52% |
| 3 Month Change | -25.49% |
| 1 Year Change | -52.50% |
| 33 Year Change | -92.40% |
| 5 Year Change | n/a |
| Change since IPO | -82.08% |
Recent News & Updates
Shareholder Returns
| BELL | GB Medical Equipment | GB Market | |
|---|---|---|---|
| 7D | -7.3% | -1.5% | 0.7% |
| 1Y | -52.5% | -3.9% | 8.7% |
Return vs Industry: BELL underperformed the UK Medical Equipment industry which returned -2.9% over the past year.
Return vs Market: BELL underperformed the UK Market which returned 8.6% over the past year.
Price Volatility
| BELL volatility | |
|---|---|
| BELL Average Weekly Movement | 5.4% |
| Medical Equipment Industry Average Movement | 6.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in GB Market | 10.4% |
| 10% least volatile stocks in GB Market | 2.6% |
Stable Share Price: BELL has not had significant price volatility in the past 3 months compared to the UK market.
Volatility Over Time: BELL's weekly volatility has decreased from 14% to 5% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 35 | Bob Rauker | www.belluscura.com |
Belluscura plc develops and commercialize oxygen related medical device products in the United States. The company offers X-PLOR and DISCOV-R, a modular portable oxygen concentrator; and related accessories. Belluscura plc was incorporated in 2015 and is based in London, the United Kingdom.
Belluscura plc Fundamentals Summary
| BELL fundamental statistics | |
|---|---|
| Market cap | UK£16.00m |
| Earnings (TTM) | -UK£14.59m |
| Revenue (TTM) | UK£1.42m |
11.3x
P/S Ratio-1.1x
P/E RatioIs BELL overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BELL income statement (TTM) | |
|---|---|
| Revenue | US$1.80m |
| Cost of Revenue | US$5.37m |
| Gross Profit | -US$3.57m |
| Other Expenses | US$15.04m |
| Earnings | -US$18.60m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.11 |
| Gross Margin | -197.53% |
| Net Profit Margin | -1,030.73% |
| Debt/Equity Ratio | 0% |
How did BELL perform over the long term?
See historical performance and comparison